China's role in research opens access to breakthrough medicines

Breakthrough drugs are receiving accelerated approval in China thanks to the country's increasing role in global clinical trials and contribution to global databases by Chinese patients.

According to Liu Xianling, professor of the Second Xiangya Hospital of Central South University, Chinese authorities and doctors have more databases for reference when accessing a new drug for admission, thanks to the increasing quality and influence of Chinese clinic trial data.

During a launch ceremony for a lung cancer breakthrough drug in Shanghai on Saturday, guests exchanged views on China's role in global clinical trials and the reason behind accelerated adoption processes.

IMpower132, a research report on lung cancer clinical trials based on global databases, adopted plenary samples from Chinese patients and research achievements from Chinese scientists.

Lu Shun, professor of Shanghai Chest Hospital at Shanghai Jiaotong University and a Chinese participant in the IMpower132 report, said Chinese clinical trial experts are having a bigger voice in the world, which helps in providing more high-end treatment to Chinese patients.

According to data from the WHO, lung cancer posed the top threat to cancer patients in China, with 820,000 new cases in 2020. Non-small cell lung carcinoma patients account for 80 percent of lung cancer sufferers, and 75 percent of NSCLC patients are in an advance stage when diagnosed.